S&P 500   4,229.97 (+0.47%)
DOW   33,478.54 (+0.51%)
QQQ   326.49 (+0.17%)
AAPL   169.29 (+0.03%)
MSFT   288.38 (-0.27%)
META   178.36 (+0.01%)
GOOGL   119.63 (-0.06%)
AMZN   141.64 (-0.74%)
TSLA   870.12 (-1.47%)
NVDA   181.62 (+0.36%)
NIO   21.17 (+5.59%)
BABA   95.49 (+3.31%)
AMD   99.48 (+0.43%)
MU   62.74 (+2.18%)
T   18.14 (+0.72%)
CGC   3.21 (-2.43%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   119.04 (+5.88%)
AMC   25.46 (+7.56%)
PYPL   100.00 (+1.10%)
PFE   48.22 (-3.46%)
NFLX   246.21 (+0.86%)
S&P 500   4,229.97 (+0.47%)
DOW   33,478.54 (+0.51%)
QQQ   326.49 (+0.17%)
AAPL   169.29 (+0.03%)
MSFT   288.38 (-0.27%)
META   178.36 (+0.01%)
GOOGL   119.63 (-0.06%)
AMZN   141.64 (-0.74%)
TSLA   870.12 (-1.47%)
NVDA   181.62 (+0.36%)
NIO   21.17 (+5.59%)
BABA   95.49 (+3.31%)
AMD   99.48 (+0.43%)
MU   62.74 (+2.18%)
T   18.14 (+0.72%)
CGC   3.21 (-2.43%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   119.04 (+5.88%)
AMC   25.46 (+7.56%)
PYPL   100.00 (+1.10%)
PFE   48.22 (-3.46%)
NFLX   246.21 (+0.86%)
S&P 500   4,229.97 (+0.47%)
DOW   33,478.54 (+0.51%)
QQQ   326.49 (+0.17%)
AAPL   169.29 (+0.03%)
MSFT   288.38 (-0.27%)
META   178.36 (+0.01%)
GOOGL   119.63 (-0.06%)
AMZN   141.64 (-0.74%)
TSLA   870.12 (-1.47%)
NVDA   181.62 (+0.36%)
NIO   21.17 (+5.59%)
BABA   95.49 (+3.31%)
AMD   99.48 (+0.43%)
MU   62.74 (+2.18%)
T   18.14 (+0.72%)
CGC   3.21 (-2.43%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   119.04 (+5.88%)
AMC   25.46 (+7.56%)
PYPL   100.00 (+1.10%)
PFE   48.22 (-3.46%)
NFLX   246.21 (+0.86%)
S&P 500   4,229.97 (+0.47%)
DOW   33,478.54 (+0.51%)
QQQ   326.49 (+0.17%)
AAPL   169.29 (+0.03%)
MSFT   288.38 (-0.27%)
META   178.36 (+0.01%)
GOOGL   119.63 (-0.06%)
AMZN   141.64 (-0.74%)
TSLA   870.12 (-1.47%)
NVDA   181.62 (+0.36%)
NIO   21.17 (+5.59%)
BABA   95.49 (+3.31%)
AMD   99.48 (+0.43%)
MU   62.74 (+2.18%)
T   18.14 (+0.72%)
CGC   3.21 (-2.43%)
GE   78.94 (+2.33%)
F   15.82 (+2.06%)
DIS   119.04 (+5.88%)
AMC   25.46 (+7.56%)
PYPL   100.00 (+1.10%)
PFE   48.22 (-3.46%)
NFLX   246.21 (+0.86%)
NYSE:ZTS

Zoetis - ZTS Stock Forecast, Price & News

$174.41
+0.35 (+0.20%)
(As of 08/11/2022 01:34 PM ET)
Add
Compare
Today's Range
$173.27
$175.56
50-Day Range
$155.97
$182.55
52-Week Range
$154.18
$249.27
Volume
35,635 shs
Average Volume
1.63 million shs
Market Capitalization
$81.65 billion
P/E Ratio
39.55
Dividend Yield
0.77%
Price Target
$224.88

Zoetis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
28.9% Upside
$224.14 Price Target
Short Interest
Healthy
0.80% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
-0.08mentions of Zoetis in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$3.25 M Sold Last Quarter
Proj. Earnings Growth
12.18%
From $5.01 to $5.62 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

139th out of 1,112 stocks

Pharmaceutical Preparations Industry

55th out of 544 stocks

ZTS stock logo

About Zoetis (NYSE:ZTS) Stock

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. The Goldman Sachs Group decreased their price target on Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. Stifel Nicolaus decreased their price target on Zoetis from $275.00 to $225.00 and set a "buy" rating for the company in a research report on Friday, June 24th. StockNews.com downgraded Zoetis from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, April 26th. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. Finally, Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They set an "overweight" rating and a $205.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $224.14.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $174.06 on Thursday. The stock has a fifty day simple moving average of $171.81 and a two-hundred day simple moving average of $180.80. Zoetis has a 1-year low of $154.18 and a 1-year high of $249.27. The firm has a market cap of $81.48 billion, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 2.98 and a beta of 0.73. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14.

Zoetis (NYSE:ZTS - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The company had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the previous year, the business earned $1.19 earnings per share. Zoetis's revenue was up 7.8% on a year-over-year basis. Analysts anticipate that Zoetis will post 5.01 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Stockholders of record on Thursday, July 21st will be issued a $0.325 dividend. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, July 20th. Zoetis's payout ratio is currently 29.48%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 2,167 shares of the firm's stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares of the company's stock, valued at $4,269,818.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Roxanne Lagano sold 2,167 shares of Zoetis stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company's stock, valued at $4,269,818.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kristin C. Peck sold 9,689 shares of Zoetis stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total value of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock valued at $3,250,158 over the last three months. Company insiders own 0.12% of the company's stock.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

Reviewing MannKind (NASDAQ:MNKD) & Zoetis (NYSE:ZTS)
Zoetis' (ZTS) "Outperform" Rating Reiterated at William Blair
Zoetis (ZTS) Set to Announce Quarterly Earnings on Thursday
Zoetis Inc. (NYSE:ZTS) CEO Sells $1,744,020.00 in Stock
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 6/1 Dividend
4/20/2022
Dividend Payable
6/01/2022
Ex-Dividend for 9/1 Dividend
7/20/2022
Last Earnings
8/04/2022
Today
8/11/2022
Dividend Payable
9/01/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
12,100
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$224.14
High Stock Price Forecast
$264.00
Low Stock Price Forecast
$202.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
8 Analysts

Profitability

Net Income
$2.04 billion
Pretax Margin
32.04%

Debt

Sales & Book Value

Annual Sales
$7.78 billion
Cash Flow
$5.84 per share
Book Value
$9.78 per share

Miscellaneous

Free Float
467,577,000
Market Cap
$81.65 billion
Optionable
Optionable
Beta
0.73

Social Links















ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price forecast for 2022?

8 equities research analysts have issued 12 month price targets for Zoetis' shares. Their ZTS share price forecasts range from $202.00 to $264.00. On average, they predict the company's share price to reach $224.14 in the next year. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2022?

Zoetis' stock was trading at $244.03 at the start of the year. Since then, ZTS shares have decreased by 28.6% and is now trading at $174.21.
View the best growth stocks for 2022 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ZTS earnings forecast
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings results on Thursday, August, 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by $0.02. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a trailing twelve-month return on equity of 49.03% and a net margin of 26.14%. The business's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.19 earnings per share.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Thursday, May 19th. Investors of record on Thursday, July 21st will be paid a dividend of $0.325 per share on Thursday, September 1st. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, July 20th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.30 per share and currently has a dividend yield of 0.77%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 29.48%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 23.13% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis updated its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of $4.97-$5.05 for the period. The company issued revenue guidance of $8.22 billion-$8.32 billion, compared to the consensus revenue estimate of $8.29 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Advisory Inc. (0.70%), Lazard Asset Management LLC (0.64%), Banque Pictet & Cie SA (0.50%), Brown Brothers Harriman & Co. (0.49%), JPMorgan Chase & Co. (0.49%) and California Public Employees Retirement System (0.49%). Insiders that own company stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Gregory Norden, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Robert Edward Kelly, Robert W Scully, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $174.21.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $81.55 billion and generates $7.78 billion in revenue each year. The company earns $2.04 billion in net income (profit) each year or $4.41 on an earnings per share basis.

How many employees does Zoetis have?

The company employs 12,100 workers across the globe.

Does Zoetis have any subsidiaries?

The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Holding Limited, Abaxis Europe GmbH, Abaxis Holding GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma (Bermuda) LLC, Alpharma (Luxembourg) S.A.R.L. y Compania Limitada, Alpharma (Luxembourg) S.àr.l., Alpharma Animal Health (Hong Kong) Co. Limited, Alpharma Animal Health Company, Alpharma Euro Holdings LLC, Alpharma Holdings (Barbados) SRL, Alpharma LLC, Alpharma do Brasil Ltda., Bovigen, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Mikjan Corporation, NVIP Pty Ltd, Nexvet, Nexvet Australia Pty Ltd, Nordic Fish Tech AB, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PHARMAQ LTD, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS Technika SpA, Pharmaq Analytiq AS, Pharmaq CA Panama Inc., Pharmaq Fishteq AS, Pharmaq Holding AS, Pharmaq Settvac AS, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Platinum Performance, Platinum Performance Inc., Platinum Performance Nutrition Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics LLC, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis (Thailand) Limited, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark Aps, Zoetis Deutschland GmbH, Zoetis Egypt Import LLC, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management (Shanghai) Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis International Services, Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Lab Holdings LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa (Pty) Ltd., Zoetis Spain S.L., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Taiwan Limited, Zoetis Treasury Center BVBA, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More

When was Zoetis founded?

Zoetis was founded in 2012.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.